International Journal of Hematology

, Volume 110, Issue 2, pp 197–204 | Cite as

Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan

  • Masahiro IekoEmail author
  • Mika Yoshida
  • Sumiyoshi Naito
  • Kazumasa Ohmura
  • Nobuhiko Takahashi
Original Article


Patients with lupus anticoagulant (LA), a thrombotic risk factor, along with decreased prothrombin (FII) activity are classified as lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) and occasionally show bleeding symptoms, although this is not essential for diagnosis. We treated 20 cases of LAHPS over a 3-year period. Median FII activity was 20.9% and the anti-prothrombin antibody (anti-II Ab), shown by ELISA findings, was detected in 55%. Bleeding symptoms were observed in 20%, although that finding was not correlated with FII activity or anti-FII Ab quantity. We also observed 21 LA cases with decreased activity of coagulation factors other than FII, which we have designated LAHPS-like syndrome (LLS). Among LLS patients, anti-FII Ab and bleeding symptoms were seen in 47.6% and 14.3%, respectively. Our findings suggest that bleeding in LAHPS and LLS cannot be explained only by FII activity decreased by anti-FII Ab. Low FVIII activity and the anti-FVIII antibody (anti-FVIII Ab) were detected in some LAHPS and LLS patients, making it difficult to distinguish those from acquired hemophilia A cases. Detection of anti-FVIII Ab quantity by ELISA may be useful for accurate determination, as that was not performed in our LAHPS or LLS patients.


Lupus anticoagulant Prothrombin activity Anti-prothrombin antibodies Anti-factor VIII antibodies 



We express our appreciation to Hiroko Juraku and Aiko Kumagai for their assistance with the experiments, and Yayoi Ishida for helping to prepare the manuscript.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.


  1. 1.
    Brandt DL, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the ISTH. Thromb Haemost. 1995;74:1185–90.CrossRefGoogle Scholar
  2. 2.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Throm Haemost. 2006;4:295–306.CrossRefGoogle Scholar
  3. 3.
    de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104:3598–602.CrossRefGoogle Scholar
  4. 4.
    Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147–52.CrossRefGoogle Scholar
  5. 5.
    Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthr Rheum. 2000;43:1982–93.CrossRefGoogle Scholar
  6. 6.
    Rapaport SI, Ames SB, Duvall BJ. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with anti-prothrombinase activity. Blood. 1960;15:212–27.Google Scholar
  7. 7.
    Mulliez SM, De Keyser F, Verbist C, Vantilborgh A, Wijns W, Beukinga I, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus. 2015;24:736–45.CrossRefGoogle Scholar
  8. 8.
    Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91:251–60.CrossRefGoogle Scholar
  9. 9.
    Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134:199–205.CrossRefGoogle Scholar
  10. 10.
    Hara Y, Makita M, Ishikawa T, Saeki K, Yamamoto K, Imajo K, et al. Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody. Ann Hematol. 2013;92:563–4.CrossRefGoogle Scholar
  11. 11.
    Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215–22.Google Scholar
  12. 12.
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885–91.Google Scholar
  13. 13.
    Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982–93.CrossRefGoogle Scholar
  14. 14.
    Smock KJ, Rodgers GM. Laboratory identification of lupus anticoagulants. Am J Hematol. 2009;84:440–2.CrossRefGoogle Scholar
  15. 15.
    Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247–51.CrossRefGoogle Scholar
  16. 16.
    Yoshida M, Ieko M, Naito S, Takahashi N. Lupus anticoagulant hypoprothrombinemia syndrome and similar conditions in Japan. Rinsyo Ketsueki. 2014;56:1505.Google Scholar
  17. 17.
    Carreno-Tarragona G, Morales E, Jimenez-Herrero MC, Cortes-Fornieles E, Gutierrez E, Praga M. Lupus anticoagulant-hypoprothrombinemia syndrome: a rare association in systemic lupus erythematosus. Nefrologica. 2016;36:186–8.CrossRefGoogle Scholar
  18. 18.
    Chung CH, Park CY. Lupus anticoagulant-hypoprothrombinemia in healthy adult. Korean J Intern Med. 2008;23:149–51.CrossRefGoogle Scholar
  19. 19.
    Jaeger U, Kapiotis S, Pabinger I, Puchhammer E, Kyrle PA, Lechner K. Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection. Ann Hematol. 1993;67:95–9.CrossRefGoogle Scholar
  20. 20.
    Simel DL, St Clair EW, Adams J, Greenberg CS. Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med. 1987;83:563–6.CrossRefGoogle Scholar
  21. 21.
    Yin ET, Gaston LW. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemrrh. 1965;14:88–115.Google Scholar
  22. 22.
    Jing J, Zehnder JL. Prozone effect in the diagnosis of lupus anticoagulant for the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Clin Pathol. 2016;146:262–7.CrossRefGoogle Scholar
  23. 23.
    Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published date. Blood Adv. 2017;1:2637–42.Google Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, School of DentistryHealth Sciences University of HokkaidoTobetsuJapan
  2. 2.Division of Clinical LaboratoryHealth Sciences University HospitalTobetsuJapan

Personalised recommendations